Publish date:

The Next Big Thing in Biotech: Hepatitis Drugs

Senior columnist Adam Feuerstein says hepatitis drugs are the next big thing to watch in biotech.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.

TheStreet Recommends